‘Clin­i­cal su­pe­ri­or­i­ty’: di­azepam nasal spray il­lus­trates FDA pa­ra­me­ters for or­phan drug ex­clu­siv­i­ty

Thanks to the last user fee agree­ment, known as the FDA Reau­tho­riza­tion Act of 2017, the agency can now ex­plain why a new­ly ap­proved or­phan drug is clin­i­cal­ly su­pe­ri­or to pre­vi­ous­ly ap­proved or­phan drugs and there­fore should be award­ed sev­en years of or­phan drug ex­clu­siv­i­ty.

Since 2017, the FDA has on­ly ex­plained how five treat­ments can be con­sid­ered clin­i­cal­ly su­pe­ri­or, with the lat­est com­ing last Fri­day for Neurelis Phar­ma­ceu­ti­cals’ Val­to­co (di­azepam nasal spray). The FDA ex­plains how di­azepam was pre­vi­ous­ly ap­proved as a gel ad­min­is­tered rec­tal­ly where­as Val­to­co’s in­tranasal route of ad­min­is­tra­tion is eas­i­er to use.

“In the con­text of when this drug is to be giv­en, typ­i­cal­ly in the mid­dle of a seizure event, it is in­her­ent­ly eas­i­er to ad­min­is­ter the drug to a pa­tient in­tranasal­ly than rec­tal­ly,” the FDA said.

The four oth­er drugs to ob­tain such clin­i­cal su­pe­ri­or­i­ty find­ings and win the or­phan ex­clu­siv­i­ty from the FDA since 2017 in­clude:

  • Pfiz­er’s My­lotarg (gem­tuzum­ab ozogam­icin) in Sep­tem­ber 2017, af­ter it was ini­tial­ly with­drawn from the mar­ket fol­low­ing an ac­cel­er­at­ed ap­proval in 2000, but was ap­proved lat­er for a low­er dose and dif­fer­ent sched­ule that was found to have less ear­ly mor­tal­i­ty, less he­pa­to­tox­i­c­i­ty, less veno-oc­clu­sive dis­ease, more rapid platelet re­cov­ery and less he­m­or­rhage, the FDA said.
  • CSL Behring’s Hizen­tra (Im­mune Glob­u­lin Sub­cu­ta­neous (Hu­man), 20% Liq­uid) in March 2018 be­cause the pre­vi­ous­ly ap­proved in­tra­venous for­mu­la­tion re­quires a cen­tral ve­nous ac­cess de­vice, which is as­so­ci­at­ed with an in­creased risk of throm­boem­bol­ic events and ac­cess-as­so­ci­at­ed in­fec­tions.
  • Astel­las Phar­ma’s Pro­graf (tacrolimus gran­ules for oral sus­pen­sion) in May 2018 be­cause “tacrolimus gran­ules for oral sus­pen­sion pro­vides an age ap­pro­pri­ate for­mu­la­tion for pe­di­atric pa­tients that avoids the se­vere risks as­so­ci­at­ed with er­ro­neous­ly com­pound­ed tacrolimus,” the FDA said.
  • No­var­tis’ Sig­ni­for LAR (pasireotide) in June 2018 for the treat­ment of Cush­ing’s dis­ease be­cause FDA said the dos­ing reg­i­men of the long-act­ing re­lease (once month­ly) pro­vides a ma­jor con­tri­bu­tion to pa­tient care over the dos­ing reg­i­men of the pre­vi­ous, im­me­di­ate re­lease (twice-dai­ly) ver­sion.

Mov­ing for­ward, drug de­vel­op­ers look­ing to ob­tain this “clin­i­cal­ly su­pe­ri­or” tag for their or­phan prod­ucts should look to 21 CFR 316.3(b)(3), which de­fines how a drug can pro­vide a sig­nif­i­cant ther­a­peu­tic ad­van­tage over an al­ready ap­proved drug (that is oth­er­wise the same drug) in one or more of the fol­low­ing three ways:

“(i) Greater ef­fec­tive­ness than an ap­proved drug (as as­sessed by ef­fect on a clin­i­cal­ly mean­ing­ful end­point in ad­e­quate and well con­trolled clin­i­cal tri­als). Gen­er­al­ly, this would rep­re­sent the same kind of ev­i­dence need­ed to sup­port a com­par­a­tive ef­fec­tive­ness claim for two dif­fer­ent drugs; in most cas­es, di­rect com­par­a­tive clin­i­cal tri­als would be nec­es­sary; or

(ii) Greater safe­ty in a sub­stan­tial por­tion of the tar­get pop­u­la­tions, for ex­am­ple, by the elim­i­na­tion of an in­gre­di­ent or con­t­a­m­i­nant that is as­so­ci­at­ed with rel­a­tive­ly fre­quent ad­verse ef­fects. In some cas­es, di­rect com­par­a­tive clin­i­cal tri­als will be nec­es­sary; or

(iii) In un­usu­al cas­es, where nei­ther greater safe­ty nor greater ef­fec­tive­ness has been shown, a demon­stra­tion that the drug oth­er­wise makes a ma­jor con­tri­bu­tion to pa­tient care.”

For more on the de­ter­mi­na­tions, the FDA pub­lish­es sum­maries of the clin­i­cal su­pe­ri­or­i­ty find­ings when a drug is el­i­gi­ble for or­phan drug ex­clu­siv­i­ty. The FDA Law Blog al­so of­fers more in­for­ma­tion on some of the su­pe­ri­or­i­ty de­ter­mi­na­tions be­fore 2017.


RAPS: First pub­lished in Reg­u­la­to­ry Fo­cus™ by the Reg­u­la­to­ry Af­fairs Pro­fes­sion­als So­ci­ety, the largest glob­al or­ga­ni­za­tion of and for those in­volved with the reg­u­la­tion of health­care prod­ucts. Click here for more in­for­ma­tion.

Author

Zachary Brennan

managing editor, RAPS

Ven­ture Cap­i­tal as a Strate­gic Part­ner: Fu­el­ing In­no­va­tion be­yond Fi­nance

The average level of investment required for a biotech start-up to succeed is increasing every year, elevating the pressure even further on venture capital to make smart financial investments. Financial investment alone, however, does not always guarantee that exciting innovations can be transformed into real businesses that make a meaningful difference to patients.

Beyond just capital

At Astellas Venture Management (AVM) – a wholly-owned venture capital organization within Astellas, headquartered in the San Francisco Bay Area – capital is just one of the ingredients we offer to add value to our biotechnology investments and partnerships. We generally take a strategic investor approach for companies in our invested portfolio, providing access to expertise, technology and/or resources in addition to the injection of finance. An equity investment from AVM can include access to Astellas’ research and development (R&D) capabilities and expertise, and a global network of partner academic institutions and biotechnology companies, to help advance and accelerate the start-up’s innovation.

UP­DAT­ED: Ver­tex joins Mer­ck, Pfiz­er — re­vamp­ing multi­bil­lion-dol­lar tri­al strat­e­gy as biotech R&D crum­bles

You can add Pfizer, Merck and — as we found out Friday morning — Vertex to the growing list of pharma giants hitting the pause button on a range of clinical trials. But not everyone in R&D is getting a red light.

Vertex says that it’s doing its best to keep working its pipeline strategy, coming up with a plan “to enable virtual clinic visits and home delivery of study drug to ensure study continuity and medical monitoring, and to facilitate study procedures.”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 76,800+ biopharma pros reading Endpoints daily — and it's free.

Covid-19 roundup: In­ter­cept, blue­bird and a grow­ing list of biotechs feel the pain as pan­dem­ic man­gles FDA, R&D sched­ules

Around 100 staffers at Boston area hospitals have now tested positive for Covid-19, spotlighting the growing risk that the pandemic will sideline many of the most essential workers in healthcare as caseloads peak in the US and around the globe. With more than 3,400 deaths, Spain has become the latest country to surpass the official death count attributed to the new coronavirus in China, where the outbreak originated. As of Thursday morning, confirmed global cases had crossed 470,000 and the death count eclipsed 21,000.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 76,800+ biopharma pros reading Endpoints daily — and it's free.

Af­ter crit­ics lam­bast­ed Gilead for grab­bing the FDA's spe­cial rare drug sta­tus on remde­sivir, they're giv­ing it back

Two days after Gilead won orphan drug status for remdesivir as a potential treatment for Covid-19, they’re handing it back.

The company was slammed from several sides after Gilead reported that the FDA had come through with the special status, which comes with 7 years of market exclusivity, the waiver of FDA fees and some tax credits as well. Typically, everyone who can get orphan status lands it without much of a fuss, but Democratic presidential candidate Bernie Sanders, Public Citizen and other consumer groups were outraged.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 76,800+ biopharma pros reading Endpoints daily — and it's free.

Mod­er­na CEO Stéphane Ban­cel out­lines a short path for emer­gency use of a coro­n­avirus vac­cine

NIAID director Anthony Fauci has left no doubts that it takes 12 to 18 months to get a new vaccine tested and in commercial use, in the best of circumstances. But in times of a global emergency — like these — maybe there’s another, faster route to follow.

In an SEC filing on Tuesday, Moderna $MRNA staked out a record-setting pathway to getting their mRNA vaccine into the frontline of the healthcare response as early as this fall. The SEC filing notes that CEO Stéphane Bancel told Goldman Sachs that an emergency use approval could allow the vaccine to go to healthcare workers and certain individuals in a matter of months — presumably provided the NIH sees the safety and efficacy data they would need from the Phase I.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 76,800+ biopharma pros reading Endpoints daily — and it's free.

Caught in a Covid-19 mael­strom, Eli Lil­ly locks down clin­i­cal tri­als as multi­bil­lion-dol­lar R&D ops de­rail

The Covid-19 pandemic has derailed Eli Lilly’s $6 billion R&D operations.

The pharma giant reported Monday morning that it has decided to hit the brakes on most new study starts and pause enrollment for most ongoing studies. Lilly adds that it is continuing dosing for ongoing studies, “but with study-by-study consideration.”

The pandemic has severely disrupted healthcare systems around the globe, says Lilly, making it difficult or impossible to conduct studies at many research sites. And there’s no timeline for when it expects to get back on track.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 76,800+ biopharma pros reading Endpoints daily — and it's free.

As share buy­backs come un­der scruti­ny, what's in store for the bio­phar­ma in­dus­try?

Stock buybacks are not to be permitted for companies that will be bailed out in the coronavirus stimulus package, Congressional leaders have signaled. To what degree the biopharma industry has relied on buybacks for earnings growth in recent years, and if the trend continues, are the big questions as scrutiny into the practice heightens and balance sheets weaken with the coronavirus pandemic wreaking havoc on global economies.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 76,800+ biopharma pros reading Endpoints daily — and it's free.

A Sin­ga­pore VC rais­es $200M for a new round, but will Covid-19 pre­vent it from rais­ing the rest?

A top Singaporean biotech venture fund is nearly halfway toward its largest ever fund, but in a sign of what could be in store for VCs amid a global economic freeze, said they could face headwinds raising the other half.

Vickers Venture Partners has secured $200 million out of a targeted $500 million for its 6th fund, first announced in early 2018. They’ve given themselves 13 months to complete the financing, Vickers founder Finian Tan told Deal Street Asia, but the financial frost settling amid the Covid-19 pandemic could slow efforts.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 76,800+ biopharma pros reading Endpoints daily — and it's free.

Strug­gling Unum ex­ecs are ready to con­sid­er a sale, merg­er or any deal that comes its way

Unum $UMRX is working its way through a survival plan of sorts.

After getting hit with a trio of FDA holds in its brief public history and triggering its second pivot to a new lead drug program while laying off 60% of the staff, the troubled penny stock biotech Unum Therapeutics has hatched new plans to secure financial backing while lining up a go-forward strategy for the company.

First, Lincoln Park Capital Fund has agreed to buy up to $25 million of the long-suffering stock, as Unum directs. And the executive team — led by CEO Chuck Wilson — has put everything on the table for consideration: a sale, acquisition, merger, licensing deal, you name it. The ACTR707 program, meanwhile, is being formally wrapped up — their second failed lead program.